GYN

CMECNE

Pregnancy of Unknown Location – Next Steps

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Define ‘a pregnancy of unknown location’
2. Discuss the use of uterine aspiration in the setting of a pregnancy of unknown location

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from March 12 2018 through 07/15/2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the test and evaluation. Upon registering and successfully completing the test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

SUMMARY:

Pregnancy of unknown location is defined as a pregnancy where intrauterine or ectopic location cannot be confirmed.

If the location cannot be definitively determined

Pregnancy of unknown location requires follow up and a diagnosis
If patient is clinically stable and pregnancy is desired
- Repeat transvaginal ultrasound and/or serial measurement of hCG

Uterine Aspiration to Determine Pregnancy Location

Perform uterine aspiration if pregnancy is not progressing normally (see ‘Related ObG Topics’ below)

Chorionic villi present
- Indicates failed uterine pregnancy
- No further follow-up needed
Chorionic villi absent
- Monitor hCG levels 12 to 24 hours after aspiration
- hCG plateau (decrease <10% to 15%) indicates the following possible scenarios
  - Uterine evacuation incomplete
  - Ectopic pregnancy, but not seen on ultrasound
- hCG decrease ≥50%
  - Monitor with serial hCG measurements
  - Treat if patient becomes symptomatic or levels plateau or increase
- hCG decrease between 15% and 50%
  - Individualize treatment
  - Follow-up with serial hCG measurements
  - Treat if (1) patient becomes symptomatic, (2) levels plateau or increase, (3) there is clinical suspicion or (4) strong risk factors for ectopic pregnancy are present

Determination of Pregnancy Location Prior to Methotrexate (MTX) Use

Arguments against determining location prior to MTX
- Delay in MTX treatment may result in a potentially preventable tubal rupture
Arguments for determining location prior to MTX
- Limits MTX exposure to those patients who actually need it
- Confirmation/knowledge of true location may impact management of current and future pregnancies
- Risk of rupture appears to be low if patient is closely monitored

KEY POINTS:

Choice of uterine aspiration should be based on shared decision making
- Discuss risk of MTX and birth defects if location not confirmed and intrauterine pregnancy continues
Consider MTX if following met
- Confirmed or high clinical suspicion of ectopic pregnancy
- Hemodynamically stable
- Unruptured mass
- No absolute contraindications to MTX
Absolute MTX Contraindications include
- Intrauterine Pregnancy | Breastfeeding | Immunodeficiency | Blood Dyscrasias | Clinically Important Hepatic Dusfunction | Active Pulmonary Disease | Active Peptic Ulcer Disease | Clinically Important Renal Dysfunction | Patient sensitive to MTX | Inability to Participate in Follow-up
Relative MTX Contraindications
- Gestational Sac > 4 cm (TV ultrasound) | High Quantitative HCG (qHCG) | Positive FH | Refusal to Accept Blood Transfusion

Learn More – Primary Sources:

ACOG Practice Bulletin 193: Tubal Ectopic Pregnancy 

Take a post-test and get CME credits

TAKE THE POST TEST

Get Guideline Notifications Direct to Your Phone

ObGFirst® – Try It Free! >>

< Previous

All GYN Posts

Next >

Pregnancy of Unknown Location – Next Steps